Physiomics awarded further contracts with Merck
Physiomics
1.50p
16:49 26/04/24
0.00%
0.00p
Oncology drug development consultancy Physiomics said on Friday that it had been awarded two further contracts by existing client Merck.
FTSE AIM All-Share
755.28
17:14 26/04/24
n/a
n/a
Health Care Equipment & Services
11,713.81
16:59 26/04/24
-0.20%
-23.76
Physiomics said the contracts, expected to be completed by the end of 2021, involved simulations of the clinical efficacy of drug products in Merck's DNA damage/repair portfolio.
Chief executive Dr Jim Millen said: "Merck remains a key, valued client and we are pleased to be continuing to work with them on a number of important development programs."
As of 0910 BST, Physiomics shares were down 0.66 at 6.06p.